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Objective: Sleep problems and depression are common symptoms in dementia with Lewy bodies (DLB),
where patients typically experience subjectively poor sleep quality, fatigue and excessive daytime sleep-
iness. However, whilst sleep disturbances have been linked to depression, this relationship has not re-
ceived much attention in DLB. The present cross-sectional study addresses this by examining
whether depressive symptoms are specifically associated with subjective sleep quality and daytime sleep-
iness in DLB, and by examining other contributory factors.
Methods: DLB patients (n=32) completed the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness
Scale (ESS) and the 15-item Geriatric Depression Scale (GDS-15). Motor and cognitive functioning was also
assessed. Pearson correlations were used to assess the relationship between GDS-15, ESS and PSQI scores.
Results: GDS-15 scores were positively associated with both ESS (r=0.51, p<0.01) and PSQI (r=0.59,
p<0.001) scores.
Conclusions: Subjective poor sleep and daytime sleepiness were associated with depressive symptoms in
DLB. Given the cross-sectional nature of the present study, the directionality of this relationship cannot
be determined, although this association did not appear to be mediated by sleep quality or daytime sleep-
iness. Nevertheless, these findings have clinical relevance; daytime sleepiness or poor sleep quality might
indicate depression in DLB, and subsequent work should examine whether the treatment of depression
can reduce excessive daytime sleepiness and improve sleep quality in DLB patients. Alternatively, more
rigorous screening for sleep problems in DLB might assist the treatment of depression. # 2015 The
Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons, Ltd.
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Introduction
Dementia with Lewy bodies (DLB) is a common
cause of dementia and accounts for 15–20% of all
dementia cases post-mortem (Holmes et al., 1999).
Individuals with DLB display a range of symptoms,
which include motor and neuropsychiatric problems,
attentional, executive function and visuospatial defi-
cits, autonomic dysfunction and fluctuating levels of
alertness, which is a key feature of DLB (McKeith
et al., 2005; McKeith, 2006).
Sleep disturbances are extremely common in indi-
viduals with DLB, where the main sleep problem is
REM behaviour disorder (RBD), which refers to the
inability to maintain muscle atonia during REM sleep.
This symptom has been investigated in detail: RBD
can predate the occurrence of Lewy body disease, is as-
sociated with various DLB clinical and pathological
features and may have a prevalence of up to 70% in
this condition (Ferman et al., 2004; Dugger et al.,
2012; Iranzo et al., 2013; Murray et al., 2013; Ferman
et al., 2014). Other sleep disturbances, such as poor
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subjective sleep quality, are also prevalent in DLB, and
are more severe than those observed in patients with
Alzheimer’s disease (AD), despite similar levels of im-
pairment (Ferman et al., 2014). In particular, daytime
sleepiness is a very common and troublesome feature
of DLB (Boot et al., 2013).
The aetiology of non-RBD sleep disturbances are
currently poorly understood in DLB. For example,
with regards to poor sleep quality, it is unclear
whether this is because of the presence of concurrent
neuropsychiatric symptoms such as hallucinations
and agitation; both of which can cause nocturnal sleep
disturbances, or whether this is because of the concur-
rent use of psychotropic medication (Bliwise et al.,
2011). Although large-scale studies of the prevalence
of non-RBD sleep disorders in DLB are currently lack-
ing, one in-hospital study of 29 patients indicated that
sleep apnoea and restless legs are both common symp-
toms in DLB, with frequencies of 30.7% and 50% re-
spectively (Terzaghi et al., 2013). Also of relevance
are nocturnal motor symptoms, which are particularly
common in those with parkinsonism (Grandas and
Iranzo, 2004), although it is not known whether the
severity of motor symptoms can affect sleep quality
in DLB. Similarly, despite the high prevalence of ex-
cessive daytime sleepiness in DLB, it is unclear
whether there is a direct link between poor sleep qual-
ity and daytime sleepiness in this population. Conse-
quently, there is a lack of well-evidenced treatments
for these symptoms in DLB.
One potential risk factor for sleep disruption in
DLB is the presence of depressive symptoms. Depres-
sion is a common symptom in patients with DLB, with
an estimated prevalence of up to 60% (Fritze et al.,
2011). The relationship between depressive symptoms
and sleep is well-characterised in non-dementia popu-
lations. Large-scale studies in older adults have ob-
served associations between depression and poor
sleep; in a normative sample of 1506 older men and
women in the United States (aged 55–84 years), indi-
viduals with depressive symptoms displayed a higher
probability of experiencing several insomnia symp-
toms, and daytime sleepiness, compared to individuals
without depressive symptoms (Foley et al., 2004). Sim-
ilarly, one cross-sectional study of 3051 men (aged
67years and older) showed that depressive symptoms,
as measured using the 15-item Geriatric Depression
Scale (GDS-15), were strongly associated with subjec-
tive sleep disturbances, specifically poor sleep quality
and daytime sleepiness (Paudel et al., 2008).
As the aetiology of subjectively poor sleep quality
and daytime sleepiness, and their relationship with de-
pressive symptoms, has yet to be established in DLB,
the aim of this cross-sectional study was to investigate
the association between depressive symptoms, subjec-
tive sleep quality and daytime sleepiness in DLB
patients.
Methods
Participants
A total of 55 patients and their informants were
approached to take part in the study from dementia
and movement disorder clinics in the North East of
England (Newcastle upon Tyne and Sunderland). To
be included in the study, participants were required
to have a diagnosis of DLB and a reliable informant
(e.g. carer or family member) who could assist with
the completion of study assessments. A total of 10 pa-
tients declined to participate in the study. Participants
were recruited sequentially in accordance with DLB
diagnostic criteria (McKeith, 2006), and the diagnosis
was confirmed by two experienced clinicians (JOB and
IGM). Participants and their informants provided
written informed consent, and the study was approved
by the local NHS Research Ethics Committee.
Procedure
Participants, with the aid of a reliable informant and
in the presence of a researcher, completed measures
of subjective sleep quality, daytime sleepiness and de-
pression. Informants were, in the majority of partici-
pants, a spouse and/or a bed partner.
Subjective sleep quality was determined using the
Pittsburgh Sleep Quality Index (PSQI; Buysse et al.,
1989), a seven-item questionnaire which assesses
self-reported sleep disturbances over the past month.
A total score of between zero and 21 is derived from
the PSQI; a cut-off value of five differentiates good
and poor sleepers and higher scores indicate poorer
sleep quality. The PSQI was also used to ask whether
snoring, long pauses between breaths, behaviours in-
dicative of RBD, or twitching or jerking legs occurred
during sleep in the previous month. Subjective day-
time sleepiness was assessed using the Epworth Sleep-
iness Scale (ESS; Johns, 1991), where higher scores
reflect a greater degree of daytime sleepiness and a
score of more than 10 reflects excessive daytime sleep-
iness. Depression was assessed using the GDS-15
(Yesavage et al., 1982), a yes/no questionnaire where
scores of between zero and 15 are obtained. Higher
scores represent more depressive symptoms, and
scores of more than five indicate probable depression
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(D’Ath et al., 1994). Notably, the GDS-15 does not
contain any questions which specifically ask about
sleep quality or daytime sleepiness.
Cognitive function was also assessed using the Mini-
Mental State Examination (MMSE; Folstein et al., 1975)
and the Cambridge Cognitive Examination (CAMCOG;
Roth et al., 1986). Cognitive fluctuations were assessed
using the Clinical Assessment of Fluctuation scale
(CAF; Walker et al., 2000). Extrapyramidal motor func-
tion was assessed using Part III of the Unified Parkinson’s
Disease Rating Scale (UPDRS-III; Goetz et al., 2008).
Information regarding the duration of cognitive and
parkinsonian symptoms, and the equivalent levodopa
dose of anti-parkinsonian medication, expressed in
milligrams (mg) was also collected. Participant bodymass
index was calculated on the basis of objectively measured
height and weight data (weight(kg) /height2(m)).
Statistical analysis
The diagnosis of DLB was subsequently confirmed
neuropathologically at post-mortem for nine partici-
pants. Two participants were shown to have a diagno-
sis other than DLB following neuropathological
assessment. Seven participants provided incomplete
GDS-15, ESS or PSQI assessment data, and four par-
ticipants were unable to complete the assessments fol-
lowing consent. These participants (n=13) were
subsequently excluded from further analyses.
The primary aim of the current study was to inves-
tigate the association between depressive symptoms
and sleep quality and daytime sleepiness. Secondary
analyses examined whether there were relationships
between demographic variables (age, the durations of
cognitive and parkinsonian symptoms), clinical mea-
sures (MMSE, CAMCOG, CAF and UPDRS-III
scores) and sleep quality and daytime sleepiness as-
sessment scores (ESS and PSQI), using Pearson corre-
lations. PSQI scores were also used to classify
participants as ‘good’ (scores of 5 or below) or ‘poor’
(scores>5) sleepers in order to examine differences
in GDS-15 and ESS scores, using t-tests. Similarly,
ESS scores were used to classify participants as not
excessively sleepy (indicated by ESS scores of 10 or
below) or excessively sleepy (ESS scores>10), and dif-
ferences in GDS-15 and PSQI scores were examined
using t-tests.
As a secondary analysis, GDS-15, ESS and PSQI
scores were compared between DLB patients who
were, and who were not, taking antidepressant medi-
cation (n=6), cholinesterase inhibitors (n=10),
levodopa medications (n=6) or sleeping medications
(n=9), using t-tests or Mann–Whitney U tests, where
appropriate. Only two participants were taking atypi-
cal antipsychotic medications (risperidone and
quetiapine), and these data were not analysed further.
Results
Complete GDS-15, PSQI and ESS data were obtained
from a final sample of 32 participants (Mage=76.16years,
SDage=7.03years), 18 of which (56.3%) had bed part-
ners. Demographic and clinical results are shown in
Table 1, and overall GDS-15, PSQI and ESS scores
indicated poor subjective sleep, excessive daytime
sleepiness and probable depression in the group of
DLB patients. A total of 21 participants (65.6%) had
a GDS-15 score of >5, 13 participants (40.6%) had
PSQI scores of >5 and 19 participants (59.4%) had
an ESS score of >10. Bed partners reported that in
the previous month, eight participants (25%) experi-
enced snoring, six participants (18.75%) displayed be-
haviours indicative of RBD, two participants (6.25%)
experienced long pauses between breaths during sleep
and 10 (31.3%) participants experienced twitching or
jerking legs during sleep.
No demographic or clinical variables (including the
levodopa equivalent dose; range 50–400mg) were sig-
nificantly associated with either ESS or PSQI scores.
Additionally, ESS and PSQI scores were not signifi-
cantly related (r=0.33, p>0.05). Primary analyses
indicated that GDS-15 scores were significantly posi-
Table 1 Participant demographic and clinical features (n = 32)
Mean SD
Age 76.16 7.03
Gender (male/female) 18 M (56.3%)/14 F (43.8%)
Duration of cognitive
symptoms (years)
2.60 1.99
Duration of parkinsonian
symptoms (years)
1.77 1.38
Body mass index (kg/m2) 25.39 3.15
GDS-15 5.66 3.45
PSQI 5.28 3.77
ESS 11.66 6.08
MMSE 17.66 4.88
CAMCOG 64.27 10.94
UPDRS-III 29.09 15.29
Levodopa equivalent dose (mg)1 225.00 133.23
CAMCOG, Cambridge Cognitive Examination; ESS, Epworth
Sleepiness Scale, GDS-15, Geriatric Depression Scale (15-item),
MMSE, Mini-Mental State Examination; PSQI, Pittsburgh Sleep
Quality Index; UPDRS-III, Part III of the Unified Parkinson’s Dis-
ease Rating Scale.
1n = 6.
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tively associated with ESS scores (r=0.51, p<0.01)
and that GDS-15 scores were significantly positively
associated with PSQI scores (r=0.59, p<0.001), dem-
onstrating that more severe depressive symptoms were
associated with excessive daytime sleepiness and
poorer sleep quality. These relationships are
summarised in Table 2. When patients were separated
into ‘good’ (n=19) or ‘poor’ sleepers (n=13) on the
basis of PSQI scores, poor sleepers displayed signifi-
cantly higher GDS-15 scores (t(30)=3.63, p<0.01)
but not ESS scores (t(30)=1.41, p>0.05) than good
sleepers. When patients were separated into those who
were not excessively sleepy (n=13) and those who
were excessively sleepy (n=19), on the basis of ESS
scores, those who were excessively sleepy had signifi-
cantly higher GDS-15 scores (t(29.53)=3.62,
p<0.01), but not PSQI scores (t(30)=1.63,
p>0.05).
There were no significant differences in ESS, PSQI
or GDS-15 scores between those who were, and were
not, currently taking antidepressant medication or
cholinesterase inhibitors (all p-values>0.05). Partici-
pants who were taking medications containing levo-
dopa showed significantly higher PSQI scores
compared to those who were not, indicating worse
sleep quality (U=36, p<0.05), but did not show any
differences in ESS or GDS-15 scores. Participants
who were taking sleeping medications had significantly
higher ESS (U=53.5, p<0.05), PSQI (U=53,
p<0.05) and GDS-15 scores (U=37.5, p<0.01), indi-
cating a greater degree of excessive daytime sleepiness,
worse sleep quality and greater depressive symptoms.
Discussion
This study examined the association between depres-
sion and subjective sleep quality and daytime sleepi-
ness in individuals with DLB. These results indicate
that depressive symptoms are associated with both
subjective sleep quality and daytime sleepiness in
DLB. However, disease severity, expressed in terms
of cognitive function or disease duration, was unre-
lated to sleep quality or daytime sleepiness. Similarly,
motor symptom severity was not directly associated
with either sleep quality or daytime sleepiness. This
suggests that excessive daytime sleepiness and poor
sleep quality in DLB may be driven more by depressive
symptoms than cognitive or motor symptoms. This
finding is in agreement with a previous study con-
ducted in individuals with DLB, which observed that
the severity of motor symptoms, and objective sleep
quality in the preceding night, were not primarily re-
sponsible for daytime sleepiness (Ferman et al., 2014).
Daytime sleepiness and sleep quality were also un-
related to the presence or severity of cognitive fluctua-
tions in the present study. It is possible that this is
because of the choice of fluctuation scale used, as
one study has observed a relationship between
informant-rated fluctuations and daytime sleepiness,
on the basis of the Mayo Fluctuations Scale (Ferman
et al., 2014). However, this study also objectively
assessed daytime sleepiness on the basis of a multiple
sleep latency test, and notably Ferman and colleagues
found that there was no association between fluctua-
tions and objective sleepiness. In addition, a separate
study did not observe a relationship between objective
intra-individual measures of cognitive fluctuation, and
intra-individual measures of objective alertness, as de-
termined by a maintenance of wakefulness test
(Bliwise et al., 2014), and thus it may be that cognitive
fluctuations are not directly related to sleep or arousal.
Importantly, these results indicate that sleep prob-
lems are associated with depression, which is common
in DLB (Fritze et al., 2011), suggesting that excessive
daytime sleepiness or poor sleep quality may be a sign
of depression in DLB. Speculatively, these results are
suggestive of a common aetiology linking depression
and daytime sleepiness in DLB; one explanation may
be that both are driven by deficits in the noradrenergic
system. DLB patients exhibit a loss of noradrenergic
neurons in the locus coeruleus which may have impacts
on arousal, cognition and mood (Szot et al., 2006;
Benarroch, 2009). As norepinephrine can directly or
indirectly contribute to the wake-promoting effects
of certain medications (Mitchell and Weinshenker,
2010), treatment options for daytime sleepiness in
DLB may therefore include noradrenergic agents. Cer-
tainly, there is some evidence to suggest that drugs such
as modafinil or admodafinil may be beneficial for this
purpose (Boeve et al., 2012) and it would be relevant
to explore whether these agents can also improve
mood. Whilst it is a possibility that sleep and
Table 2 Pearson correlations between measures of depressive
symptoms, daytime sleepiness and sleep quality (n = 34)
GDS-15 ESS PSQI
GDS-15 —
ESS 0.51* —
PSQI 0.33 0.59** —
Notes:
ESS, Epworth Sleepiness Scale, GDS-15, Geriatric Depression
Scale (15-item); PSQI, Pittsburgh Sleep Quality Index.
*p< 0.01.
**p< 0.001.
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depression are related to the same biological substrate,
it is possible that the presence of depressive symptoms
might cause sleep difficulties in DLB and that the
screening and treatment of depressive symptoms might
improve sleep. Alternatively, sleep difficulties may be
the cause of depressive symptoms in DLB. As both pos-
sibilities have important treatment implications in
DLB, these should be investigated in more detail.
Specific strengths of the current study include the
well-characterised nature of the patient cohort, as
the diagnosis of DLB was made by two highly experi-
enced clinicians, and neuropathological confirmation
for the diagnosis was available for nine participants.
In addition, the associations between daytime sleepi-
ness and depressive symptoms, and sleep quality and
depressive symptoms, were not because of the influ-
ence of cholinesterase inhibitors. A small number of
patients who were taking sleep medications unsur-
prisingly tended to have poorer sleep quality, as well
as excessive daytime somnolence. Similarly, patients
who were taking medications containing levodopa
(as a marker of greater disease severity) had poorer
sleep quality.
Limitations of the current study include the associa-
tive nature of the findings and the lack of objective
sleep data in this group of patients, as the data were
cross-sectional. However, this study was preliminary
in nature and is the first to confirm the association
between depressive symptoms, sleep quality, and day-
time sleepiness, in individuals with DLB. As there is a
well-established association between depression and
sleep in non-dementia groups (Foley et al., 2004;
Paudel et al., 2008), it is possible that a bi-directional
relationship between depressive symptoms and sleep
quality, and between depressive symptoms and day-
time sleepiness, exists in DLB. Future research should
examine whether the severity of depressive symptoms,
or concurrent neuropsychiatric symptoms such as
nocturnal visual hallucinations, which are common
in DLB, can influence the degree of daytime sleepiness,
or sleep quality, in DLB. A longitudinal study would
clarify the directionality of this relationship and con-
firm whether depression precedes daytime sleepiness
and poor sleep quality in DLB. This has been shown
in one non-DLB community study in a South Korean
sample of adults over 65 years of age (Kim et al., 2009).
Larger comparative studies may also be useful in iden-
tifying whether the relationships between sleep and
depressive symptoms are more severe in DLB than in
other dementias, or healthy aged individuals. Addi-
tionally, future studies may also wish to employ the
use of sleep diaries, from which more detailed sleep
continuity data can be derived, thus allowing the
relationship between specific aspects of subjective
sleep quality and depressive symptoms to be examined
in greater detail.
The examination of sleep and depression in DLB
may be particularly salient in early or prodromal dis-
ease stages, as both sleep and depressive symptoms
may antedate the manifestation of dementia by many
years (Donaghy et al., 2015). Additionally, future re-
search should further clarify the reliability and validity
of commonly used sleep measures, such as the PSQI
and ESS, in dementia populations. Finally, it is possi-
ble that the presence of sleep disordered breathing,
restless legs syndrome (RLS) or periodic limb move-
ments (PLMs) may have affected sleep in the DLB
group we examined, although there was no reason to
expect these participants should show different rates
to those previously reported (Terzaghi et al., 2013).
However, a detailed large-scale assessment of the prev-
alence of RLS or PLMs, and the subsequent effects
upon sleep, has yet to be conducted in this patient
group (Iranzo et al., 2007).
Conclusions
Depressive symptoms are associated with subjectively
worse sleep quality and excessive daytime sleepiness
in individuals with DLB. These results potentially indi-
cate that the treatment of depressive symptoms may
result in corresponding improvements to subjective
sleep quality and daytime sleepiness in DLB. Excessive
daytime sleepiness or poor sleep quality may also be a
sign of depression in DLB, and might suggest that
more rigorous screening for depression is warranted
in DLB in order to aid the treatment of sleep
difficulties.
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Key points
• Poor sleep quality and excessive daytime sleepiness
are common in DLB.
• Poor sleep quality and daytime sleepiness are
associated with depressive symptoms.
• The treatment of depressive symptoms may
improve sleep, and daytime sleepiness, in DLB.
• Potential bi-directional relationships between sleep
and mood in DLB need further examination.
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